| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Gomisin D are not fully characterized in the available literature. As a dibenzocyclooctadiene lignan from Schizandra chinensis, it belongs to a class of compounds known for various biological activities including hepatoprotective, anti-inflammatory, antioxidant, and anticancer effects. The lignans from Schisandra species are known to interact with multiple cellular targets, including cytochrome P450 enzymes, nuclear receptors, and signaling pathways involved in oxidative stress response and inflammation. Gomisin D likely shares some of these target interactions, but detailed target identification studies are limited. Further research is needed to fully elucidate the molecular targets and mechanisms of action of this compound.
|
|---|---|
| ln Vitro |
In vitro bioactivity studies on Gomisin D are limited. The compound has been identified and characterized as a constituent of Schizandra chinensis fruits. Based on the known activities of related Schisandra lignans, Gomisin D may exhibit antioxidant, anti-inflammatory, and hepatoprotective activities in cell-based assays. Schisandra lignans have been shown to protect hepatocytes from chemical-induced damage, reduce oxidative stress, and modulate inflammatory responses. However, specific in vitro activity data for Gomisin D, including IC50 values or detailed cellular mechanism studies, are not widely available in the published literature. The compound's activity profile remains to be fully characterized through systematic pharmacological studies.
|
| ln Vivo |
In vivo studies on Gomisin D are limited. As a natural product isolated from Schizandra chinensis, it is presumed to contribute to the pharmacological effects of the crude plant extract, which has been used traditionally for liver protection and as a general tonic. The in vivo activities of Gomisin D specifically have not been extensively studied, and detailed animal model data are not available in the current literature. Related Schisandra lignans have demonstrated hepatoprotective effects in animal models of liver injury, as well as anti-inflammatory and adaptogenic activities. However, these effects cannot be directly attributed to Gomisin D without specific studies. Further in vivo investigations are needed to establish the pharmacological profile of this compound.
|
| Enzyme Assay |
The experimental protocols for studying Gomisin D typically begin with the extraction and isolation of the compound from Schizandra chinensis fruits. Plant material is dried, ground, and extracted with organic solvents such as ethanol or methanol. The crude extract is then subjected to chromatographic separation techniques, including column chromatography, preparative HPLC, or flash chromatography, to isolate pure Gomisin D. The identity and purity of the isolated compound are confirmed using analytical techniques such as NMR spectroscopy, mass spectrometry, and HPLC. For receptor binding studies, standard radioligand binding or fluorescence-based assays can be adapted to evaluate interactions with potential targets.
|
| Cell Assay |
Cell-based experimental protocols for Gomisin D typically involve culturing relevant cell lines and treating them with varying concentrations of the compound. Common cell lines used for studying Schisandra lignans include hepatocytes (such as HepG2 cells) for liver protection studies, and various cancer cell lines for anticancer activity screening. Cells are cultured in appropriate media and treated with Gomisin D for specified time periods. Cell viability is assessed using MTT or CCK-8 assays. For mechanistic studies, cells are harvested and analyzed for markers of oxidative stress, inflammation, or apoptosis using Western blotting, quantitative PCR, or ELISA. However, detailed protocols specific to Gomisin D are not extensively documented in the literature.
|
| Animal Protocol |
In vivo animal studies for Gomisin D are not well-documented in the available literature. For similar Schisandra lignans, typical in vivo protocols involve the use of mouse or rat models of liver injury (induced by chemicals such as carbon tetrachloride or acetaminophen), inflammation models, or metabolic disease models. The compound is administered orally or intraperitoneally at various doses, and efficacy is assessed by measuring biochemical markers in blood and histopathological analysis of tissues. However, specific experimental protocols for Gomisin D have not been published. Researchers interested in studying this compound would need to develop protocols based on the known activities of related lignans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Gomisin D are not available in the current literature. As a natural product lignan, it would be expected to have moderate oral bioavailability and undergo metabolic transformation in the liver. The compound has a molecular formula of C28H34O10 and a molecular weight of approximately 530.57. For research purposes, Gomisin D is typically stored as powder at -20degC for up to 3 years or at 4degC for up to 2 years. Solubility information is not widely reported, but related lignans are typically soluble in organic solvents such as DMSO, ethanol, and methanol. Detailed pharmacokinetic parameters such as half-life, clearance, and bioavailability have not been determined for this compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for Gomisin D are not available in the published literature. As a natural product from Schizandra chinensis, which has a long history of traditional use, the compound is presumed to have a reasonable safety profile. Schisandra fruits have been consumed as a traditional medicine and food supplement with no major safety concerns reported. However, the specific toxicity profile of purified Gomisin D has not been systematically evaluated in preclinical studies. Standard toxicological assessments, including acute toxicity, repeat-dose toxicity, and genotoxicity studies, would be needed to establish the safety profile of this compound for any potential therapeutic applications.
|
| References | |
| Additional Infomation |
Reports indicate that (11R,12R,15S,24S,25S)-12,25-dihydroxy-18,19,20-trimethoxy-11,12,24,25-tetramethyl-4,6,9,14-tetraoxapentane[13.7.3.03,7.08,22.016,21]pentadecan-1,3(7),8(22),16,18,20-hexene-13-one has been found in Schisandra chinensis and Schisandra chinensis.
Gomisin D is a research-grade natural product isolated from Schizandra chinensis fruits. It is a dibenzocyclooctadiene lignan with a molecular formula of C28H34O10 and a molecular weight of approximately 530.57. The compound is used primarily for phytochemical research, natural product chemistry studies, and as a reference standard for the analysis of Schisandra constituents. Schizandra chinensis is a well-known medicinal plant in traditional Chinese medicine, and its lignans are studied for various pharmacological activities including hepatoprotection, neuroprotection, and anti-aging effects. Gomisin D is one of many bioactive lignans found in this plant. The compound is not approved for clinical use and is available only for research purposes. |
| Molecular Formula |
C28H34O10
|
|---|---|
| Molecular Weight |
530.5636
|
| Exact Mass |
530.215
|
| CAS # |
60546-10-3
|
| PubChem CID |
5317799
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
698.5±55.0 °C at 760 mmHg
|
| Melting Point |
194ºC
|
| Flash Point |
229.3±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
3.95
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
38
|
| Complexity |
871
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H]1CC2=CC3=C(C4=C2C5=C(C(=C(C=C5[C@@H]([C@@]1(C)O)OC(=O)[C@]([C@@H](CO4)C)(C)O)OC)OC)OC)OCO3
|
| InChi Key |
VLLFEMVDMFTBHG-KMIFWYFFSA-N
|
| InChi Code |
InChI=1S/C28H34O10/c1-13-8-15-9-18-22(37-12-36-18)24-19(15)20-16(10-17(32-5)21(33-6)23(20)34-7)25(27(13,3)30)38-26(29)28(4,31)14(2)11-35-24/h9-10,13-14,25,30-31H,8,11-12H2,1-7H3/t13-,14+,25-,27-,28+/m0/s1
|
| Chemical Name |
(11R,12R,15S,24S,25S)-12,25-dihydroxy-18,19,20-trimethoxy-11,12,24,25-tetramethyl-4,6,9,14-tetraoxapentacyclo[13.7.3.03,7.08,22.016,21]pentacosa-1,3(7),8(22),16,18,20-hexaen-13-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~188.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.71 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8848 mL | 9.4240 mL | 18.8480 mL | |
| 5 mM | 0.3770 mL | 1.8848 mL | 3.7696 mL | |
| 10 mM | 0.1885 mL | 0.9424 mL | 1.8848 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
